Lung Cancer News and Research

Latest Lung Cancer News and Research

Steak and ticks: A potentially life-threatening experience

Tick bites can trigger a severe, delayed allergic reaction to red meat, suggest findings published in the Journal of General Internal Medicine.

27 Jul 2012

Long-term use of reverse geometry lenses may induce inflammatory response

Continuous long-term overnight use of reverse geometry lenses results in a significantly increased presence of inflammatory mediators compared with wearing 30-night silicone-hydrogel contact lenses or wearing no lenses, show study results.

27 Jul 2012

Diabetes cutoffs don’t quite cut it for South Asians

Individuals of South Asian origin may require closer monitoring for Type 2 diabetes, suggest researchers.

27 Jul 2012

Potential biomarker to predict lung cancer patients' response to chemotherapy

Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press on July 26th in the journal Cell Reports.

27 Jul 2012

LPL deficiency treatment poised to be first gene therapy in Europe

For the first time, the European Medicines Agency has recommended gene therapy for approval in Europe.

26 Jul 2012

Fatty acids normalize without help in girls with eating disorders

Omega-3 essential fatty acid supplementation is unnecessary for adolescent girls with eating disorders and weight-loss eating disorder, as levels normalize once they return to normal weight, say researchers.

26 Jul 2012

Visual impairment hampers elderly patients’ self-management

Elderly patients with visual impairment need extra support to help them manage their medications, report UK researchers.

26 Jul 2012

Virginia Hospital Center offers new Calypso System for patients with prostate cancer

Virginia Hospital Center is among the few hospitals along the east coast to offer the new Calypso® System featuring GPS for the Body technology and Beacon electromagnetic transponders for patients with certain types of cancer.

26 Jul 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, today announced that the first patient has been treated in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma (HCC), or liver cancer, who have not received treatment with sorafenib—the current standard of care for this patient population.

26 Jul 2012

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.

26 Jul 2012

MRI useful for identifying bone lesions in diabetic feet

Identification of specific bone lesions in the feet of patients with diabetes can be achieved with magnetic resonance imaging, show study findings.

25 Jul 2012

New tool uses fluorescence to distinguish cancerous tissue from normal one in low-grade tumors

A new probe developed collaboratively at Norris Cotton Cancer Center and Dartmouth College's Thayer School of Engineering uses an innovative fluorescence-reading technology to help brain surgeons distinguish cancerous tissue from normal tissue. The probe tool, now already in use at the Cancer Center for brain surgery, may one day be used for surgeries for a variety of cancers.

25 Jul 2012